ArticleBlood cancer journal2023
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis.
Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis.Blood advances · 2026Article
- Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.Bone marrow transplantation · 2026Article
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.HemaSphere · 2026Article
- Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.Future oncology (London, England) · 2026Observational
- From myeloma to POEMS: extending the potential of T-cell redirecting therapies.Haematologica · 2026Article
- Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharmaceutical research · 2025Review
- Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.HemaSphere · 2025Article
- Article
- Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis.European journal of haematology · 2025Article
- Injection site reaction to teclistamab in a patient with multiple myeloma.JAAD case reports · 2025Article
- Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.Annals of hematology · 2025Article
- Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.JACC. Asia · 2025Article
- Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.Frontiers in immunology · 2025Review
- High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy.Bone marrow transplantation · 2024Article
- Review
- Treatment of AL amyloidosis in the era of novel immune and cellular therapies.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.